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Studies showed that speciﬁc probiotics provide therapeutic beneﬁts in inﬂammatory bowel disease. In vitro evidence suggested
that Lactobacillus paracasei also called ST11 (CNCM I-2116) is a potent strain with immune modulation properties. However,
little is known about its capacity to alleviate inﬂammatory symptoms in vivo In this context, the main objective of this study
was to investigate the role of ST11 on intestinal inﬂammation using the adoptive transfer mouse model of experimental colitis.
Rag2−/− recipient mice were fed with ST11 (109 CFU/day)a month prior to induce colitis by adoptive transfer of naive T cells.
One month later, in clear contrast to nonfed mice, weight loss was signiﬁcantly reduced by 50% in ST11-fed mice. Further
analysis of colon specimens revealed a signiﬁcant reduction neutrophil inﬁltration and mucosal expression of IL1β, IL-6, and IL12
proinﬂammatory cytokines, whereas no consistent diﬀerences in expression of antibacterial peptides or tight junction proteins
were observed between PBS and ST11-fed mice. All together, our results demonstrate that oral administration of ST11 was safe
and had a signiﬁcant preventive eﬀect on colitis. We conclude that probiotics such as Lactobacillus paracasei harbor worthwhile in
vivo immunomodulatory properties to prevent intestinal inﬂammation by nutritional approaches.
1.Introduction
Probiotics are deﬁned as live microbial food supplements
that when ingested can survive gastrointestinal tract and
exert positive inﬂuence on host health. The mode of action
of probiotics is complex and not yet fully elucidated.
Many mechanisms have been reported to explain probiotic
actions such as antagonism against intestinal pathogens,
enhancement of mucosal barrier activity, or modulation of
host’s immune functions as recently reviewed in [1].
Inﬂammatory bowel disease (IBD) is a term used to
cover a large range of immune-mediated diseases with
not well-deﬁned aetiology that results in chronic relapsing
inﬂammation of the gut. The two major forms of IBD are
Crohn’sdiseaseandulcerativecolitis.Geneticpredispositions
as well as environmental factors such as diet or composition
and activity of intestinal microbiota have been implicated
in IBD pathogenesis [2]. Experimental colitis induced by
adoptive transfer (ECIBAT) of na¨ ıve T cells in lymphopenic
mice is an established animal model for IBD sharing a
numberofclinical,genetic,andimmunologicalfeatureswith
the human disease [3, 4]. Thus, ECIBAT is considered as one
of the most relevant models to study IBD pathogenesis or to
design and evaluate therapies.
In rodents, diﬀerent probiotic cocktails (some are
already commercially available) were eﬀective in preventing
or reducing gut inﬂammation when administrated before
inducing intestinal injury. Forinstance,considerablebeneﬁts
in animals fed with a combination of lactic acid-producing
bacteria (LAB) were reported with Lactobacillus salivarius
and Biﬁdobacterium infantis, YO-MIX Y 109 FRO (3 strains
of LAB), IRT5 (5 strains of LAB), or VSL#3 (8 strains of2 Clinical and Developmental Immunology
LAB) [5–13]. Some probiotic feeding protocol signiﬁcantly
reduced intestinal disease severity with weight loss reduction
and or improvement of colon pathology over the exper-
imental period [1, 14–16]. However, the clinical studies
with IBD patients fed with the same probiotic cocktails are
either missing or did not systematically and consistently
induce clinical remission. The studies made so far underline
the need to further study and understand IBD in order
to optimize the potential nutritional solution to ameliorate
IBD.
Lactobacillus paracasei ST11 (NCC2461) was previously
shown to adhere to intestinal epithelial cell line and have
antimicrobial activity in vitro [17–19]. It was also shown that
ST11 decreases nonrotavirus diarrhea in infants [19, 20]. We
also observed that daily intake of ST11 tends to interfere
with Helicobacter pylori colonization in healthy infants
and adults [21, 22]. ST11 strains provide convincing and
interesting health beneﬁts associated with gastrointestinal
tract physiology, however, no evidences exist concerning
potential protection against intestinal inﬂammation. Herein,
the main objectives of this work were to complete our
knowledge on ST11 in vitro properties and to evaluate the
protective properties of ST11 in a mouse model of ECIBAT.
2.MaterialsandMethods
2.1. Animals. Wild-type (WT) or Rag2−/− C57BL/6 mice
were purchased from CDTA Orleans (France). Mice were
maintained in speciﬁc pathogen-free conditions at Nestl´ e
Research Center animal care facility. Female mice were
used around 7 weeks of age and ST11-fed for the next 8
weeks (4 weeks pre- and postcolitis induction) as described
below. All experiments were conducted according to the
Nestl´ e Research Center use and care of experimental animal
committee and approved by Swiss governmental veterinary
oﬃces (authorisation number VD2076). All animal display-
ing signs of pain or >10% weight loss have to be prematurely
killed.
2.2.ProbioticBacteriaCulture,Administration,andDetection.
LactobacillusparacaseiST11(NCC2461)bacteriaweregrown
inMRSbr othat37 ◦Cfor16–18h,andthennumberofviable
cells was determined by agar plate counting and/or OD600
measurements. For in vitro experiments, fresh cultures were
used, whereas ST11 bacterial stocks were made in PBS with
10% glycerol and kept frozen at −80◦C until used for in vivo
experiments. Each day a vial was thawed, extensively washed,
and resuspended in PBS before administration by gavage
to each animal. ST11-fed animals received 109 CFU of live
bacteria daily in 200μL PBS, whereas control received only
PBS. Mice were fed from the beginning until the end of the
study.
2.3. Bone Marrow-Derived Dendritic Cell Culture and Stimu-
lation. C57BL/6 bone marrow-derived dendritic cells (BM-
DCs) were diﬀerentiated in vitro using previously described
protocol [23]. BM-DC were harvested, washed, and counted
for stimulation after 5–7 days culture in Iscove’s modiﬁed
Dulbecco medium (IMDM) supplemented with 10% heat-
inactivated fetal calf serum, 100U/mL penicillin, 100μg/mL
streptomycin, 5mM β-mercaptoethanol (all Sigma), and
10ng/mL of human recombinant Fms-like tyrosine kinase
3 ligand (FLT3L, R&D systems). We obtained in routine
>95% of immature CD11c+ BM-DC as estimated by ﬂow
cytometryanalysis(FACSCalibur,BectonDickinson)oflive-
gated cells. BM-DCs were matured by 24 hours incubation
with ST11, lipopolysaccharide (LPS, E.coli 055:B5, Sigma),
or lipotecho¨ ıc acid (LTA, S. aureus, Sigma) at indicated
concentrations.BM-DCphenotypicmaturationwasassessed
by anti-CD40, -CD80, and -CD86 staining and ﬂow cytom-
etry analysis of live CD11b+CD11c+cells. All antibodies were
purchased from eBiosciences. Additionally, as an indication
of BM-DC functional activation, proinﬂammatory cytokine
expression was assessed by ELISA as described below.
2.4. T Helper Cell Diﬀerentiation Assay. CD4+ Tc e l l sw e r e
isolated from spleen and lymph nodes of WT mice. Sus-
pensions were labeled with PE-conjugated antimouse CD4
and CD4+ T cells enriched using the anti-PE magnetic cell
sorting system (Miltenyi Biotec) according to manufacturer’s
instructions. Enriched CD4+ T cells (∼85% pure, as esti-
mated by ﬂow cytometry) were then labeled with FITC-
conjugated antimouse CD45RB and PE.Cy7-conjugated
a n t i m o u s eC D 2 5 .N a i v eTc e l l sw e r es o r t e do naF A C S
Aria(BectonDickinson)beingCD4+CD25−CD45RBhigh and
>99% pure on reanalysis. Freshly generated BM-DC and
sorted naive T cells were cocultured in 96-ﬂat bottom plates
in 200μL volume of complete IMDM, containing 1×104
BM-DC and 2.5×104 sorted naive CD4+ T cells, stimulated
with immobilized anti-CD3 (clone 3C11, 5μg/mL) and
soluble anti-CD28 (clone 37.51, 1μg/mL). Exogenous TGFβ
(5ng/mL, R&D systems), and a given concentration of ST11,
L P S ,o rL T Aw e r ea d d e di no r d e rt og e to p t i m a lTh e l p e r
cell diﬀerentiation [24]. T helper cells diﬀerentiation was
assessed after 4 days of coculture by ﬂow cytometry analysis.
Cells were stimulated 4 hours with PMA (50ng/mL) and
ionomycin (1μg/mL), treated with brefeldin A (5μg/mL)
in the last two hours (all from Sigma), then harvested,
cell surface stained with anti-CD4, then ﬁxed and per-
meabilized with Cytoﬁx/Cytoperm (Becton Dickinson), and
intracellularly stained with anti-IL-17 and anti-IFNγ.T h 1
cells were CD4+IFNγ+ whereas Th17 cells were CD4+IL17+.
Mesenteric lymph node cell suspensions were also made and
treated as above to assess in adoptively transferred mice
Th1 cells and Th17 cells ex vivo. Additionally, anti-FoxP3
staining was made in order to track the generation of so
called CD4+FoxP3+ regulatory T cells. All antibodies were
purchased from eBiosciences.
2.5. Colitis Induction and Morphological Assessment of Colonic
Damages. To induce colitis, 5×105 sorted naive CD4+ T
cells in 200μL PBS were adoptively transferred i.p. into PBS-
or ST11-fed Rag2−/− mice then mice continued on their diet.
Recipient mice were weighted initially and thereafter 3 times
perweek.Alongtheexperiment,micewereobservedforclin-
ical signs of illness: hunched-over appearance, piloerection,Clinical and Developmental Immunology 3
diarrhea, and blood in the stool. In order to respect internal
animal welfare policy (minimizing animal suﬀering), the
regular protocol was shortened to avoid development of
severe illness and mice were killed 4 weeks after T-cell
transfer. No obvious signs of piloerection, diarrhea and
blood in stools were observed within this period. Colonic
tissue samples (systematically taken at mid-colon) were
ﬁxed in PBS containing 10% neutral-buﬀered formalin and
paraﬃne m b e d d e d5 μm sections were made and stained
with hematoxylin and eosin (H&E). The sections were
analyzed under light microscopy without prior knowledge of
the type of treatment.
2.6. Myeloperoxidase and Cytokine Measurements. Ultrasen-
sitive multiplex cytokine proﬁling kit (Meso ScaleDiscovery)
was used to assess mouse IL-1β, IL-6, KC (mouse IL-8), IL-
10, IL-12p70, IFNγ,a n dT N F α in culture supernatants or
whole colonic protein extracts according to manufacturer’s
instructions. IL-23 was measured in culture supernatants
with standard ELISA kit (R&D systems). Myeloperoxidase
(MPO) content of the colon protein extracts was determined
with a mouse MPO ELISA kit (Hycult Biotech) following
the manufacturer’s instructions. When indicated cytokines
or MPO levels were normalized to total tissue protein
contents.
2.7. Total Protein and RNA Preparation. Total colon was cut
longitudinally in two pieces snap frozen and stored at −80◦C
until protein and total RNA extraction were done respec-
tively. Proteins from colon samples were prepared in RIPA
buﬀer(Sigma)andproteinmeasuredwithbicinchoninicacid
assay kit (Thermo scientiﬁc). RNA preparation was made
with RNADVANCE kit following manufacturer’s instruc-
tions (AGENCOURT). Total RNA quality was assessed by
Agilent RNA 6000 Nano LabChip Kit (Agilent Technologies)
andquantiﬁcationdonewithRibogreenRNAQuantiﬁcation
Kit (Molecular Probes).
2.8. Real-Time PCR. Total RNA (1 μg) was reverse-tran-
scribed using Multiscribe Reverse Transcriptase (Applied
Biosystems) following manufacturer’s instructions. The
cDNA was stored at −20◦C until use. Then, 1μL of cDNA
was mixed with 9μL of reaction mix containing 5μL2 X
Syber Green Master Mix +3.6μL RNAse free Water +0.4μL
Oligo Mix (11.35μM of forward and reverse primers) per
well in a 384 well plates. Forward (fwd) and reverse (rev)
primer sequences used for speciﬁc gene expression are
available upon request. Real-time PCR was performed using
the 7900 real-time PCR device (Applied Biosystem) with
standard cycling conditions. The expression level of each
gene is indicated by the number of cycles needed for the
cDNA ampliﬁcation to reach a threshold (Ct values). The Ct
valueforeachgenewasnormalizedtothehousekeepinggene
GAPDH. Relative mRNA expression value was calculated
using the following formula: ΔCt=Ct of the gene of
interest−Ct of GAPDH in the same sample, and mRNA
relative expression was calculated based on the formula
2−(ΔCtcontrol)−(ΔCtcolitis) for each sample.
2.9. Statistical Analysis. All the data presented herein are
expressed as mean ± SD. Comparison between groups was
made using student’s t-tests for unpaired data when said
or nonparametric Wilcoxon tests with the software SAS 9.1
when appropriate. Diﬀerences were considered statistically
signiﬁcant for P value<0.05.
3. Results
3.1. ST11 Mediated DC Activation and Helper T Cell Diﬀer-
entiation. The eﬀect of ST11 on DC function was evaluated
in vitro by analyzing maturation and cytokine production of
immature BM-DCs exposed to diﬀerent stimuli. BM-DCs
were exposed 24h with ST11 at ratio of 100 bacteria per
cell. Results were compared to immature BM-DCs cultured
in medium alone or exposed to LPS (0.1μg/mL) or LTA
(1μg/mL) as positive control. Maturation pattern of BM-
DCs was assessed by ﬂow cytometry analysis of surface
marker expression (Figure 1(a)) and ELISA determination
of cytokine release in the culture supernatants (Figure 1(b)).
As LPS and LTA, ST11 induced clear CD40, CD80, CD86
costimulatory molecules upregulation (Figure 1(a)). Next,
we assess cytokine expression in supernatants. As LPS and
LTA, ST11-mediated activation of BM-DC induce important
secretion of proinﬂammatory cytokines (IL-1β,I L - 6 ,I L -
8, IL-12, IFNγ,a n dT N F α), as well as important amount
of IL-10 which is an anti-inﬂammatory cytokine. Recently,
anti-inﬂammatory probiotic properties were screened and
distinguished according to their ability to preferentially
induce IL-10 or IL-12 secretion, and strains leading to
higher IL-10/IL-12 ratio were very potent in reducing TNBS-
mediated intestinal inﬂammation [10, 25, 26]. Interestingly,
ST11-activated BM-DCs made more IL-10 than IL-12 with
an IL-10/IL-12 ratio of 2.91±1.54.
As DC phenotype and cytokine expression tailor-speciﬁc
immune responses in vivo, we evaluated whether ST11-
mediated BM-DC activation support speciﬁc T cell polariz-
ing activity. BM-DC and sorted na¨ ıve CD4+ Tc e l lc o c u l t u r e s
(DC-T) were made in the presence of diﬀerent doses
of LPS, LTA, or ST11. In classical coculture conditions
(anti-CD3+ anti-CD28 stimulation without TGFβ), almost
exclusively IFNγ+ producing T cells (so-called Th1 cells)
were obtained (about 70%), whereas few if not any IL-
17+ producing T cells (so-called Th17 cells) were found
(<2%) (Figure 2(a), left panel). As recently described by
Veldhoen and colleagues [24], TGFβ introduction in T-DC
coculture is necessary to initiate Th17 diﬀerentiation. Thus,
by introducing TGFβ into coculture, we restore in vitro Th17
diﬀerentiation (about 60%) and reduce Th1 diﬀerentiation
(<2%) (Figure 2(a), right panel). Using the same protocol
and diﬀerent modulatory signals (i.e., LPS, LTA, or ST11)
at diﬀerent doses (ratio raging from 0.01–1μg/mL or 1:1
to 100:1 bacteria:cell), we studied how activated BM-
DCs drive Th1 or Th17 diﬀerentiation. LPS and LTA-
activated BM-DCs orchestrate in a dose-dependent manner
Th1 diﬀerentiation in TGFβ-free cocultures (Figure 2(b))
and Th17 diﬀerentiation in TGFβ-containing cocultures
(Figure 2(c)). Surprisingly, in clear contrast to LPS or LTA,4 Clinical and Developmental Immunology
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Figure 1: ST11 induces phenotypic DC maturation and speciﬁc cytokine release pattern. (a) 5×105 BM-DCs were cultured for 24h in
the absence (Unstim.) or the presence of ST11 (at bacteria:DC ratio of 100:1). As positive control LPS or LTA stimulations were used at
1μg/mL. CD40, CD80, and CD86 expressions were determined by ﬂow cytometry. Representative dot plots are shown in the left panel,
and mean ﬂuorescent intensity values ±SD for three separate experiments are shown in the right bar graph. (b) 5×105 BM-DCs were
cultured for 24h in the absence (Unstim.) or the presence of ST11 (at bacteria:DC ratio of 100:1), LPS (0.1μg/mL), or LTA (1μg/mL),
then supernatants were analyzed by multiplex ELISA. Results are mean values ±SD obtained in three independent cultures and expressed in
pg/mL of supernatants for each condition.Clinical and Developmental Immunology 5
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Figure 2: ST11 weakly supports Th17 cell diﬀerentiation in DCT cells cocultures. (a) BM-DCs were cocultured with sorted na¨ ıve CD4+
T cells for 4 days at DC:T cell ratio of 1:2.5 in the absence or the presence of TGFβ (5ng/mL). Then, cells were stimulated, ﬁxed,
and intracellularly stained for T helper 1 (Th1 being IFNγ+) or T helper 17 (Th17 being IL-17+) cell quantiﬁcation by ﬂow cytometry.
Representative dot-plots are shown, numbers indicate % of a gated population. Combination of proinﬂammatory signals and TGFβ are
mandatory for Th17 cell diﬀerentiation. (b) Bar graphs represent mean % values ±SD of Th1 (CD4+ IFNγ+ IL-17− T cells, black-ﬁlled bars)
and Th17 (CD4+ IFNγ− IL-17+ T cells, unﬁlled bars) obtained in three independent experiments in the absence (a) or the presence (c) of
TGFβand analyzed by ﬂow cytometry. As proinﬂammatory signal, either LPS, LTA, or ST11 was used in a dose-dependent manner. Doses
are given in ng/mL for LPS and LTA or bacteria: DC ratio for ST11.6 Clinical and Developmental Immunology
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free cocultures (Figure 2(b)) and very poor Th17 inducers in
TGFβ-containing cocultures (Figure 2(c))c o m p a r e dt oL P S
or LTA.
3.2. ST11-Fed Mice Are Protected against Colitis Induction. In
our protocol, ST11 eﬃciently colonize GIT (data not shown)
as previously described in mouse and human [18, 20]a n d
displayed interesting in vitro immunomodulatory properties
(above results), therefore we tested whether ST11 could be a
potent anti-inﬂammatory strain in vivo allowing protection
against intestinal damages associated with IBD. To test this
hypothesis, we triggered colitis in rag2−/− mice by adoptive
transfer of sorted na¨ ıve T-cells. ECIBAT model of chronic
intestinal inﬂammation was chosen because it induces a
colonic inﬂammation which is closer to human IBD than
other chemically-induced colitis models [27].
ST11 feeding was not associated with signiﬁcant diﬀer-
ence in body weight before colitis induction as compared
to vehicle PBS-fed mice (Figure 3(a) lower part). After
colitis induction, ST11 feeding continues during 4 weeks
posttransfer. Then, development of colitis was followed over
time by measuring body weight, stool consistency, and
general animal welfare. Marked and signiﬁcant diﬀerences in
body weight loss were observed around week 3 posttransfer
between PBS-fed and ST11-fed colitic mice. We found that
ST11 feeding was eﬀective in protection against colitis as
weight loss was signiﬁcantly reduced by ∼50% at week
4 post transfer compared to PBS-fed control mice with
a mean of 3.6% versus 8.2% of initial body weight loss
(Figure 3(a), black and red diamonds). In contrast, rag2−/−
healthy mice (PBS-fed, no T-cell transfer) slightly gain
weight (Figure 3(a), empty diamonds). No other diﬀerences
in macroscopic parameters were found between ST11-fed
and PBS-fed mice. Speciﬁc colon inﬂammation provoked
a twofold increase in weight/length (W/L) ratio in colitic
mice compared to healthy mice but there was no marked
eﬀect of ST11 feeding. Notably, at 4 weeks post transfer,
inﬂammation was localized to the colon and did not
extend into the jejunum or ileum section of small intestine.
Next, histological examination of H&E stained sections of
colon at week 4 after colitis induction were made, some
mucosal ulceration, hyperplasia and muscular thickening
were equally observed in both PBS-fed and ST11-fed groups
(Figure 3(a)). However, we observed a lesser neutrophil
and mononuclear cell inﬁltrates in ST11-fed compared to
PBS-fed colitic mice. As MPO is by far the most abundant
protein product in azurophilic granules of neutrophils and
is found in other polynuclear leukocytes, monocytes, and
macrophages [28], we decided to measure MPO levels in
order to unambiguously conﬁrm our histological obser-
vations. We detected a signiﬁcant reduction of colonic
MPO level in ST11-fed compared to PBS-fed colitic mice
(119.9±9.8 versus 212.6±37.3ng/mg of total proteins);
whereas in healthy mice, MPO levels measured were very
low (29.9±3.3ng/mg of total proteins) (Figure 3(b)). All
together, our results revealed that feeding ST11 strongly
diminish development of colitis.
3.3. Immunological Features of ST11-Fed versus PBS-Fed Col-
itic Mice. In IBD patients or mouse models of IBD, colitis is
primarily mediated by dysregulated mucosal DCs activation
and pathogenic Th1 and Th17 eﬀector T-cells generation
[29–32]. Therefore, as a reﬂection of mucosal immune cell
contents [33], we extensively analyzed mesenteric lymph
node (MLN) cell phenotype and function in order to get
insights into ST11-mediated protection. Based on in vitro
results presented above, we pay attention to DC and T-cell
subsets with a side by side comparison between healthy WT
or colitic CD4+ T cells and DC phenotype and function.
PBS-fed or ST11-fed rag2−/− who received na¨ ıve T cells
by adoptive transfer (AT) were eﬃciently colonized by CD4+
T cells. CD4+ T cells represent about 60% of live-gated lym-
phocytes in the MLN preparations. Non-T-cell-transferred
rag2−/− mice do not contain T cells, therefore wild-type
(WT) mice were used as control and contained about 38%
CD4+ Tcellswithinthelive-gatedlymphocytes(Figure4(a)).
In colitic PBS-fed or ST11-fed rag2−/− mice, T cells were
the progeny of adoptively transferred T cells. Phenotypical
characterization by ﬂow cytometry supports their activated
phenotype being CD45RBlow and CD62L− in contrast to
na¨ ıve CD45RBhigh CD62L+ T cell inoculum. Transferred
cells also express gut-homing classical markers CD103 and
β7 integrin (Figures 4(b) and 4(c)). No numerical or
phenotypicaldistinctionscanbemadebetweenbothPBS-fed
andST11-fedcoliticmice.CD4+FoxP3+ regulatoryTcellsare
known to suppress pathogenic eﬀector cells through cell-to-
cell contact or accumulation at the inﬂamed sites [31, 34–
39]. Some probiotics have been shown to stimulate na¨ ıve T-
cells conversion into Treg in vitro and in vivo and might at
least partly explain probiotic immune functions [7, 12, 38].
Thus,weevaluatedwhetherTregcellswereenrichedinST11-
fed mice at mucosal inﬂammatory sites. FoxP3 staining did
not reveal any signiﬁcant diﬀerence in Treg cell numbers
betweenPBS-fedandST11-fedcoliticmice.Indeed,allcolitic
mice contained about 3% Treg whereas healthy WT mice
contained about 13% of CD4+FoxP3+ cells (Figure 4(d)).
Additionally, T cells were stimulated ex vivo and IFNγ
and IL-17 expression measured by ﬂow cytometry. As
expected, colitic mice were enriched in Th1 (CD4+IFNγ+)
and Th17 (CD4+IL17+) cells with about 22% and 2–5%
respectively, whereas healthy WT mice contained few if not
any of them (<0.5%) (Figure 4(e)). However, no signiﬁcant
diﬀerences can be found between PBS-fed and ST11-fed
colitic animals. All together, these results ruled out a general
ST11-mediated alleviation of inﬂammation by limiting gut
homing, expansion, activation, and/or diﬀerentiation of
transferred na¨ ıve T cells into lymphopenic recipients.
Next, we evaluated whether ST11-protective eﬀects were
associated to altered DC homeostasis in colitic mice. Both in
human IBD patients and murine colitis models, pathology
is associated with the local accumulation of activated DCs,
that is, alterations in mucosal DC subsets are thought to
contribute to the eﬀector pathways that lead to IBD as
recently reviewed in [40]. In our colitic mice, we con-
ﬁrmed CD11c+ DC abundance (about 30% of live gated
cells) in MLN preparations (Figure 5(a)), whereas CD11c+
DC population represented less than 2-3% of live gatedClinical and Developmental Immunology 7
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Figure 3: ST11 feeding inhibits colitis development induced by adoptive transfer of na¨ ıve T cell in Rag2−/− mice. (a) 6–8 Rag2−/− mice
either PBS-fed (black diamonds, right graph) or ST11-fed (red diamonds, middle graph) were adoptively transferred with 5×105 sorted
na¨ ıve cells. Recipient mice were weighted 3 times a week. As negative control, a group of nontransferred Rag2−/− mice was used (empty
diamond, left graph). Weight changes (in % of initial body weight) of control or recipient mice ±SD are shown. Average weight in grams
±SD at the enrollment (i) and at day 0 before colitis induction (ii) is given for each group below the graphs. 4 weeks after cell transfer,
mice were sacriﬁced and assessed for histopathology. Inserts are representative H&E stained pictures of colon sections; black bar represents
50μm (magniﬁcation×20). (b) Colonic MPO was assessed in every single mouse by ELISA and expressed in ng MPO per mg of total colonic
proteins. Student’s t-test with t, tendency P<0.1; ∗, P<0.05, and ∗∗P<0.01 versus PBS-fed mice.
lymphocytes in healthy WT mice. However, at this stage,
no signiﬁcant diﬀerences can be found between PBS-fed
and ST11-fed colitic animals. Recently, it was shown that
distinct functions are supported by diﬀerent DC subsets in
the gut where two populations of DCs were described that is,
CD11c+CD11blow/− and CD11c+CD11b+ [41, 42]. The for-
merpopulationwasreportedtobebeneﬁcialandtofavorgut
tropism by upregulation of β7 integrin and CCR9 on na¨ ıve T
cells as well as Treg induction, whereas the latter population
was reported to be detrimental by improving pathogenic
Th1 and Th17 cell diﬀerentiation. Therefore, we quan-
tiﬁed both CD11c+CD11blow/− and CD11c+CD11b+ DC
subsets. Indeed, CD11c+CD11b+ DCs were highly enriched
in colitic mice (more than half of total DCs, Figure 5(a))
and display an activated phenotype with higher level of
costimulatory CD40, CD80, and CD86 molecules compared
to their CD11c+CD11blow/− DC counterparts (Figure 5(b)).
In order to check whether this impaired balance between
CD11c+CD11blow/− and CD11c+CD11b+ DC subsets has
consequences in colitis, we plot CD11blow/−/CD11b+ DC
ratio against relative weight loss in every single mice
(Figure5(c)).Wefoundarelevantcorrelationbetweencolitis
severity and enrichment in CD11b+ DCs. Interestingly,
ST11-fed mice display less distortion in DC subsets and
suggest that ST11 reinforces or supports DC homeostasis
(ratio of 3.24, 1.13, versus 1.03 for healthy, ST11-fed colitic
and PBS-fed colitic mice, resp.). This might explain at least
partly preventive eﬀect of ST11 feeding.8 Clinical and Developmental Immunology
0
1
0
2
3
100 101 102 103 104 100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
0
1
0
2
3
100 101 102 103
0
1
0
2
3
100 101 102 103 104
104
(a) (b) (c) (d) (e)
AT and ST11-fed
AT
WT
24.2 13.6
57.6 ±7.3
61.9 ±8.6
37.9 ±0.7
25.7
64.8 4.3 4.3 2.8
2.3
2.3
22.2
21.6 16.8
28.9
65.9 3.1
4
3.3 3.9
21.7
5.8
<0.1 0.2
0.5
13.2 13.8
66
3.2 6.3 6.3
79.8
F
S
C
F
S
C
F
S
C
C
D
1
0
3
C
D
1
0
3
C
D
1
0
3
β
-
7
β
-
7
β
-
7
Gated CD4+Tc e l l s
I
L
-
1
7
I
L
-
1
7
I
L
-
1
7
F
o
x
p
3
F
o
x
p
3
F
o
x
p
3
CD45RB CD62L CD4 CD4 IFNγ
Figure 4: Phenotypic and functional characteristics of T cells after transfer. 5×105 sorted na¨ ıve T cells were adoptively transferred into
Rag2−/− mice. (a) At week 4, mesenteric lymph node cell suspensions were made, stained, and analyzed by ﬂow cytometry. CD4+ cells
repopulated PBS-fed recipient mice (AT) as eﬃciently as ST11-fed mice (AT and ST11-fed). As control, representative staining obtained
with CD4+ cells from unmanipulated C57BL/6 wild-type mice (WT) are shown (lower dot plots) because unmanipulated Rag2−/−mice do
not contain CD4+ T cells. (b-d) Phenotype of gated CD4+ T cells was assessed by FoxP3, CD45RB, CD62L, CD103, and integrin β7 staining
as well as (e) IL-17 and IFNγ secretion upon in vitro stimulation. Percentages are indicated in dot plots. Data are representative of two
independent experiments made with 3-4 animals each time.
3.4. ST11-Feeding Attenuates Proinﬂammatory Cytokines
Expression in Colon. To get more insights into how ST11
mediates its protective eﬀect against colitis, further analyses
were made on colonic samples. We evaluated the expres-
sion of several genes related to the gut immune system
and inﬂammation. Gene-expression levels for cytokines,
antimicrobial peptides and tight junction proteins were
determined by real time quantitative PCR for each sample
and normalized to the level of house-keeping GAPDH gene
expression. Modulation of gut barrier function is frequently
evoked in the literature to explain probiotic-associated
health beneﬁts [1, 15, 16]. Gut barrier function can be
achievedbyimprovingantibacterialpeptidesecretionand/or
improving epithelial integrity. In order to test whether ST11-
fed mice harbor better gut barrier condition, expression of
mRNA for speciﬁc antibacterial peptides and tight junction
proteins were quantiﬁed. Even though reduced or increased
expressions were observed for anti-bacterial peptides or tight
junction proteins mRNA respectively in colitic mice, none
of the messenger assessed was signiﬁcantly diﬀerent between
PBS-fed and ST11-fed colitic mice (Figure 6(a)). However,
we observed a tendency or signiﬁcant reduction of major
proinﬂammatory cytokines mRNA levels for IL-1β,I L - 6 ,
IL-12, IL23, IFNγ,a n dT N F α (ST11-fed/PBS-fed ratio of
relative gene expression <1, Figure 6(b), more importantly
conﬁrmed by signiﬁcant reduction in colonic protein levels
for IL-1β, IL-6, and IL-12 (Figure 7) in ST11-fed colitic mice
compared to PBS-fed colitic mice. All together, these results
suggest that ST11-mediated protection against colitis seems
to be mediated by in vivo immunomodulatory properties of
ST11 rather than gut barrier function modulation.
4. Discussion
Cellular and molecular eﬀects of probiotics are actively
studied, especially with respect to prevention and treatment
of IBD [1, 15, 16]. Probiotics are by deﬁnition safe for
human consumption, survive after ingestion within the GIT
and, mediate strain speciﬁc health beneﬁts. Their positive
eﬀects are related to microbiota modiﬁcation, improvement
gut barrier, and/or immunomodulatory properties. Herein,
we studied speciﬁcally ST11-associated immune properties
and health beneﬁts. We showed that ST11 can strongly
decrease colitis development in a preventive protocol. ST11
strain is of particular interest because its safety was already
demonstrated, and it resists GIT conditions and is found
in mouse stools as well as in human stools after feedingClinical and Developmental Immunology 9
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(data not shown and [18, 20]). Hence, we and others never
observed adverse events in ST11-fed mice or human.
Our in vitro studies improved current knowledge
on ST11-speciﬁc immunomodulatory properties. ST11-
activatedBM-DCsmademoreanti-inﬂammatoryIL-10than
proinﬂammatory IL-12 cytokines and were poor Th1/Th17
inducers. Many strains were tested and ST11 was one of
the best IL-10 inducers and the weakest Th17 inducer
(unpublished data). Molecular mechanisms behind these
observations are still under investigations. Currently, we
know that Th17 cells diﬀerentiate under the inﬂuence of
DC-derivedproinﬂammatorycytokines(IL-1β, IL-6, and IL-
23) concomitantly with TGFβ [24]. ST11-, LPS-, and LTA-
activated BM-DC produced at least similar levels of IL-1β
andIL-6,whereasIL23washardlydetectableinallconditions
in our hands. Therefore, diﬀerences in IL-1β, IL-6, or IL23
production by ST11-activated BM-DCs cannot be a reason
to explain poor Th17 diﬀerentiation in T-DC coculture in
presence of ST11. However, recently, it was shown that
IL-10 reduces Th17 generation in vitro [43, 44], therefore
we believe that reduction of Th17 diﬀerentiation with ST11-
activated DC might be due to high level of IL-10 rather than
the lack of a pro-Th17 cytokine.
Our in vivo preventive protocol demonstrated that ST11
feeding was eﬃcient in reducing colitis. In order to get more
insightsintomechanismsinvolvedinST11healthbeneﬁtson
colitis, a careful ﬂow cytometry study of mucosal regulatory
T cells, helper T cells, and DCs in colitic mice was made.
Treg generation is often associated with probiotic-mediated
protection against inﬂammation [7, 12, 38]. In our study,
ST11 neither improved Treg generation in vitro (data not
shown) nor increased Treg numbers in colitic mice. We did
not observe a signiﬁcant reduction in eﬀector T cells in
ST11-fed compared to PBS-fed colitic mice, despite a weak
Th1/Th17 generation potential in vitro. Moreover, mucosal
DC recruitment and activation was studied based on recent
evidence showing (i) probiotic feeding alters the distribution
of the DC subsets within the intestinal lymphoid tissueClinical and Developmental Immunology 11
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Figure 7: ST11 feeding reduces proinﬂammatory cytokine expres-
sion in colitic mice. Proinﬂammatory cytokine production by
colonic tissues was assessed by multiplex ELISA at 4 weeks post
transfer. Histograms show the mean value (in pg/mg of total
proteins) ±SD (from 6–8 mice per group). Black-ﬁlled, red-ﬁlled,
or empty bars were colitic PBS-fed mice (AT), colitic ST11-fed
(AT+ST11), or healthy mice (Rag2−/−), respectively. ∗, P<0.05,
and ∗∗P<0.01 versus PBS-fed mice.
[45] (ii) that impaired balance of pro-inﬂammatory CD11b+
and immunoregulatory CD11b− mucosal DCs predisposes
to colitis development [42]. Whereas ST11 feeding did not
modify eﬀector or regulatory T cell homeostasis in colitic
mice, we observed an impact on DCs subset distribution.
ST11 feeding limits CD11b+ pathogenic DCs recruitment
and/or generation. CD11b+ pathogenic DCs abundance was
clearly associated with disease severity (weight loss). It
might be interesting to further characterize these cells and
check whether ST11-feeding also aﬀect DC homeostasis in
noninﬂammed mice.
No direct correlation can be made with some in vitro
aspects obtained with ST11 culture and in vivo observations.
Thisfurthersupportsthatbeyondprimaryinvitroscreening,
thereisaneedtoassessprobioticactivityinrelevantcomplex
physiological environment that reﬂects better the real life
conditions and probiotic properties. According to literature
evidences and our in vitro experiments, our prediction was
that ST11 would protect against colitis based on reduction
of Th1/Th17 pathogenic eﬀector T-cells generation. To
some extent this hypothesis was correct but ST11-mediated
protection was not limited to reduction of pathogenic
eﬀectorT-cellsgenerationasreﬂectedbyourgeneexpression
results in PBS-fed or ST11-fed inﬂamed colons. Follow-
ing colitis induction, gut tight junction messengers were
reduced, whereas antimicrobial peptide messengers were
increased but independently of ST11 feeding. The increase
of antimicrobial defenses might reﬂect the alteration of the
gut barrier integrity initiating and/or sustaining intestinal
inﬂammatory loop by enhanced luminal bacterial translo-
cation. Improvement of gut barrier activity is a commonly
used hypothesis to explain how probiotics exert their health
beneﬁts upon inﬂammatory challenge [1, 15, 16]. However,
as ST11 feeding did not inﬂuence those gut barrier gene
expression, we ruled out this hypothesis. When colitic mice
were fed with ST11, an important and signiﬁcant reduction
of mucosal pro-inﬂammatory cytokines expression and
neutrophils recruitment was observed. Thus, we believe that
ST11exertsapivotalimmunomodulatoryroleoninnatecells
whichinitiallydampensglobalinﬂammatoryresponsesperse
thereby limiting subsequently intestinal tissue damages.
All together, the results obtained in our preventive
model of mouse colitis induction would favour a general
reduction of intestinal innate immune response rather than
any action on adaptive cell functions. We believed that ST11
mainly acts on innate cells such as DCs modifying their
a c t i v i t y .H o w e v e r ,a sw eo n l ym a d eap r e v e n t i v es t u d y ,w e
could not ﬁrmly exclude that, ST11 feeding reduces later
helper T-cell generation or maintenance which in turn could
also contribute to reduction of intestinal inﬂammation.
Other mechanisms might participate to colitis reduction in
probiotic fed animals. In ECIBAT mouse model of colitis,
rapid and uncontrolled T-cell proliferation occurred in
adoptively transferred immunodeﬁcient mice [46]. Colitis
reﬂects unregulated generation and activation of Th1 and
Th17 that inﬁltrate the colon [29]. It might be driven by
antigens from speciﬁc strain of enteric bacteria. Hence,
IBD cannot be induced in immunodeﬁcient mice reared
undergerm-freeconditions,andmajorspeciesofcommensal
bacteria are associated with IBD induction in diﬀerent
animal models [34, 47–49]. Of note, diﬀerent helicobacter
species were shown to be major IBD-elicitor strains [47–49].
Interestingly, we previously demonstrated that ST11 as well
as L. Johnsonii were able to limit Helicobacter infection in
human [21, 22, 50]. Therefore, probiotic-driven antagonism
or out-competition of natural IBD eliciting ﬂora might
also be an interesting hypothesis to test in the future as a
preventive approach to limit colitis onset.
Nutritional interventions, which are relatively easy to
carry out, could have a larger impact on immune function
than commonly appreciated. It is appealing to design
probiotic-based preventive diet in order to maintain GIT
homeostasis or prevent development of chronic inﬂamma-
tion. Herein, we show that ST11 probiotic strain harbors
immune modulating properties in vitro and in vivo which
reduce colitis. Therefore, we suggest that ST11 might be
considered as a nutritional solution for IBD patients.
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